title: Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients.
abstract: BACKGROUND
  Given the roles of receptor for advanced glycation end products (RAGE) in the pathogenesis of carcinogenesis, we propose that RAGE polymorphisms may be associated with risk of epithelial ovarian carcinoma (EOC).
  
  
  METHODS
  This case-control study included 190 women over 40 years of age who were diagnosed with primary EOC and 210 healthy control subjects. RAGE gene polymorphisms, including 82G>S,-374T>A,-429C>T,and 1704G>T were determined.
  
  
  RESULTS
  We found that only the frequencies of the 82G>S polymorphisms were significantly different between the EOC cases and controls. The 82SS genotype was significantly higher in EOC patients than in controls (37.89% vs. 23.33%,P<0.001). With the 82 GG genotype as reference, the OR for 82SS homozygous carriers reached to 2.65 (95% CI: 1.54-4.58; P =0.0004) after adjustment for age, smoking status, body mass index, family history, usage of contraceptives, tubal ligation history, use of menopausal hormones and menopausal status. The 82S allele carriage presented a higher risk for EOC (OR=1.71; 95% CI, 1.29-2.26; P=0.0002). The polymorphisms of 1704G>T,-374T>A and -429C>T did not affect the EOC risk.
  
  
  CONCLUSIONS
  This result suggests that the 82G>S polymorphism of RAGE gene may be associated with the susceptibility of EOC.
authors.affiliation: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong province, PR China.
authors.forename: Shuquan
authors.initials: S
authors.lastname: Zhang
authors.forename: Xuwei
authors.initials: X
authors.lastname: Hou
authors.forename: Sihua
authors.initials: S
authors.lastname: Zi
authors.forename: Yankui
authors.initials: Y
authors.lastname: Wang
authors.forename: Lijun
authors.initials: L
authors.lastname: Chen
authors.forename: Beihua
authors.initials: B
authors.lastname: Kong
mesh_terms: D000483:Alleles; D044466:Asian People / Q000235:genetics*; D002277:Carcinoma / Q000209:etiology / Q000235:genetics*; D000077216:Carcinoma, Ovarian Epithelial; D016022:Case-Control Studies; D002681:China; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006720:Homozygote; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000209:etiology / Q000235:genetics*; D016017:Odds Ratio; D010051:Ovarian Neoplasms / Q000209:etiology / Q000235:genetics*; D011110:Polymorphism, Genetic; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000235:genetics*; D012307:Risk Factors
chemical_list: D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic